Document Detail

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
MedLine Citation:
PMID:  17113426     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Cyclo-oxygenase-2 (COX-2) selective inhibitors have been associated with an increased risk of thrombotic cardiovascular events in placebo-controlled trials, but no clinical trial has been reported with the primary aim of assessing relative cardiovascular risk of these drugs compared with traditional non-steroidal anti-inflammatory drugs (NSAIDs). The MEDAL programme was designed to provide a precise estimate of thrombotic cardiovascular events with the COX-2 selective inhibitor etoricoxib versus the traditional NSAID diclofenac. METHODS: We designed a prespecified pooled analysis of data from three trials in which patients with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 mg or 90 mg daily) or diclofenac (150 mg daily). The primary hypothesis stated that etoricoxib is not inferior to diclofenac, defined as an upper boundary of less than 1.30 for the 95% CI of the hazard ratio for thrombotic cardiovascular events in the per-protocol analysis. Intention-to-treat analyses were also done to assess consistency of results. These trials are registered at with the numbers NCT00092703, NCT00092742, and NCT00250445. FINDINGS: 34 701 patients (24 913 with osteoarthritis and 9 787 with rheumatoid arthritis) were enrolled. Average treatment duration was 18 months (SD 11.8). 320 patients in the etoricoxib group and 323 in the diclofenac group had thrombotic cardiovascular events, yielding event rates of 1.24 and 1.30 per 100 patient-years and a hazard ratio of 0.95 (95% CI 0.81-1.11) for etoricoxib compared with diclofenac. Rates of upper gastrointestinal clinical events (perforation, bleeding, obstruction, ulcer) were lower with etoricoxib than with diclofenac (0.67 vs 0.97 per 100 patient-years; hazard ratio 0.69 [0.57-0.83]), but the rates of complicated upper gastrointestinal events were similar for etoricoxib (0.30) and diclofenac (0.32). INTERPRETATION: Rates of thrombotic cardiovascular events in patients with arthritis on etoricoxib are similar to those in patients on diclofenac with long-term use of these drugs.
Christopher P Cannon; Sean P Curtis; Garret A FitzGerald; Henry Krum; Amarjot Kaur; James A Bolognese; Alise S Reicin; Claire Bombardier; Michael E Weinblatt; Désirée van der Heijde; Erland Erdmann; Loren Laine;
Related Documents :
24071046 - Is local bone graft sufficient to maintain the surgical correction in adolescent idiopa...
7785746 - Clinical experience with tilavist: an overview of efficacy and safety.
23473906 - Incidence, significance, and natural history of persistent retrograde venous flow post-...
22841526 - Hypertonic solution decreases extravascular lung water in cardiac patients undergoing c...
24030216 - Iliococcygeus fixation or abdominal sacral colpopexy for the treatment of vaginal vault...
22728106 - Eversion carotid endarterectomy is associated with impaired postoperative hemodynamic s...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Lancet     Volume:  368     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2006-11-20     Completed Date:  2006-11-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  1771-81     Citation Subset:  AIM; IM    
Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Data Bank Information
Bank Name/Acc. No.:;  NCT00092742;  NCT00250445
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents, Non-Steroidal / adverse effects,  therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Cardiovascular Diseases / chemically induced
Cyclooxygenase 2 Inhibitors / adverse effects,  therapeutic use*
Diclofenac / adverse effects,  therapeutic use*
Middle Aged
Multicenter Studies as Topic
Osteoarthritis / drug therapy*
Pyridines / adverse effects,  therapeutic use*
Randomized Controlled Trials as Topic
Sulfones / adverse effects,  therapeutic use*
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Cyclooxygenase 2 Inhibitors; 0/Pyridines; 0/Sulfones; 15307-86-5/Diclofenac; 202409-33-4/etoricoxib
Comment In:
Lancet. 2006 Nov 18;368(9549):1745-7   [PMID:  17113403 ]
Nat Clin Pract Rheumatol. 2007 Jun;3(6):316-7   [PMID:  17406384 ]
ACP J Club. 2007 Mar-Apr;146(2):44   [PMID:  17335167 ]
Lancet. 2007 Feb 17;369(9561):555-6; author reply 556   [PMID:  17307095 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Beyond diuretics: management of volume overload in acute heart failure syndromes.
Next Document:  Unintended pregnancy and use of emergency contraception among a large cohort of women attending for ...